

CERTIFIED TRUE COPY OF THE RESOLUTION PASSED IN THE MEETING OF THE BOARD OF DIRECTORS OF THE Q-LINE BIOTECH LIMITED (FORMERLY KNOWN AS Q-LINE BIOTECH PRIVATE LIMITED) HELD AT THE REGISTERED OFFICE OF THE COMPANY AT 298-281, TRANSPORT NAGAR, KANPUR ROAD ADJACENT TRANSPORT NAGAR METRO STATION, LUCKNOW-226012, UTTAR PRADESH, INDIA ON TUESDAY, THE 30TH DAY OF SEPTEMBER 2025 AT 04:00 P.M.

APPROVAL OF DRAFT RED HERRING PROSPECTUS OF THE COMPANY

“**RESOLVED THAT** pursuant to the provisions of Section 26, 32 and other applicable provisions, if any, of the Companies Act, 2013, the Board hereby approves the Draft Red Herring Prospectus dated September 30, 2025 for the public issue of up to 70,53,200 Equity Shares of Rs. 10/- each through the SME Platform of National Stock Exchange Limited, i.e. NSE Emerge, duly initialed by the Chairman for the purpose of identification as placed before the meeting.

RESOLVED FURTHER THAT the Company, in consultation with the BRLMs, may consider a Pre-IPO placement of up to 8,00,000 Equity Shares of face value of ₹10/- each prior to filing of the Red Herring Prospectus with the RoC. The Pre-IPO Placement, if undertaken, will be at a price to be decided by the Company, in consultation with the BRLMs. If the Pre-IPO Placement is undertaken, the number of Equity Shares issued pursuant to the Pre-IPO Placement will be reduced from the Issue, subject to compliance with Rule 19(2)(b) of the SCRR. The Pre-IPO Placement, if undertaken, shall not exceed 20% of the size of the Fresh Issue. Prior to the completion of the Issue, the Company shall appropriately intimate the subscribers to the Pre-IPO Placement, prior to allotment pursuant to the Pre-IPO Placement, that there is no guarantee that the Company may proceed with the Issue, or the Issue may be successful and will result into listing of the Equity Shares on the Stock Exchanges. Details of Pre-IPO Placement, if undertaken shall be included in the Red Herring Prospectus and Prospectus.

RESOLVED FURTHER THAT all the Directors in their respective capacities along with the Chief Financial Officer and Company Secretary & Compliance officer, be and are hereby authorized to sign the declaration page of the Draft Red Herring Prospectus as an approval and verification of all the contents as mentioned in the Draft Red Herring Prospectus.

RESOLVED FURTHER THAT Saurabh Garg, Chairman & Managing Director and/ or Amita Garg, Non-Executive Director of the Company be and are hereby authorized to deliver the copy of the approved Draft Red Herring Prospectus, duly signed by all the Directors in their respective capacities along with the Chief Financial Officer and Company Secretary & Compliance officer of the Company, to the Book Running Lead Managers of the Issue i.e. Hem Securities Limited and Share India Capital Services Private Limited, for deposition of the same with NSE Emerge`.

RESOLVED FURTHER THAT any of the Directors and/ or Key Managerial Personnel of the Company be and are hereby severally authorized to do all such acts, deeds, matters and things as it may in its absolute discretion consider necessary, desirable or expedient and to sign, execute and submit all the requisite documents, in connection with the said filling of the Draft Red Herring Prospectus with NSE Emerge.

Q-LINE BIOTECH LIMITED

(Formerly known as “Q-Line Biotech Private Limited”)

RESOLVED FURTHER THAT a certified true copy of the resolution be furnished under the signature of any one Director and/or Key Managerial Personnel of the Company to the respective authorities”.

// Certified True Copy //

**For Q-Line Biotech Limited
(Formerly Known As Q-Line Biotech Private Limited)**

Q-LINE BIOTECH LIMITED

Saurabh Garg **Managing Director & Chairman**

**Saurabh Garg
Chairman & Managing Director
DIN: 02891621
Address: 280/9, Kha Blunt Square,
Durgapuri, Lucknow - 226004**

Date: September 30, 2025

Q-LINE BIOTECH LIMITED

(Formerly known as “Q-Line Biotech Private Limited”)

Regd. Office: 298-281, Transport Nagar, Kanpur Road, Adjacent. Transport Nagar Metro Station, Lucknow-226012 (U.P.), INDIA. Tel.: 0522-2433023
Delhi. Office: C-108, Naraina Industrial Area Phase -1, New Delhi, Delhi, 110028. Tel.: 011-45577407
E-mail: compliance@qlinebiotech.com | Website: www.qlinebiotech.com | CIN No.: U74120UP2010PLC042528

CERTIFIED TRUE COPY OF THE RESOLUTION PASSED IN THE MEETING OF THE BOARD OF DIRECTORS OF THE Q-LINE BIOTECH LIMITED (FORMERLY KNOWN AS Q-LINE BIOTECH PRIVATE LIMITED) HELD AT THE REGISTERED OFFICE OF THE COMPANY AT 298-281, TRANSPORT NAGAR, KANPUR ROAD ADJACENT TRANSPORT NAGAR METRO STATION, LUCKNOW-226012, UTTAR PRADESH, INDIA ON SATURDAY, THE 16TH DAY OF MAY, 2026 AT 04.00 P.M.

APPROVAL OF RED HERRING PROSPECTUS OF THE COMPANY

“RESOLVED THAT pursuant to the provisions of Section 26, 32 and other applicable provisions, if any, of the Companies Act, 2013, the Board hereby approves the Red Herring Prospectus dated May 16, 2026 for the public issue of up to 62,53,200 Equity Shares of Rs. 10/- each through the SME Platform of National Stock Exchange Limited, i.e. NSE Emerge, duly initialed by the Chairman for the purpose of identification as placed before the meeting.

RESOLVED FURTHER THAT the Company, in consultation with the BRLMs, has undertaken a Pre-IPO Placement of 8,00,000 Equity Shares by way of a private placement at an issue price of ₹343 per Equity Share (including a premium of ₹333 per Equity Share) for an aggregate consideration of ₹2744 lakhs. Accordingly, the size of the Issue has been reduced. The investors that have subscribed to the Equity Shares of our Company pursuant to the Pre-IPO Placement have been informed that there is no guarantee that the Issue may come through or the listing may happen and accordingly, the investment was done by the relevant investors solely at their own risk.

RESOLVED FURTHER THAT all the Directors in their respective capacities along with the Chief Financial Officer and Company Secretary & Compliance officer, be and are hereby authorized to sign the declaration page of the Red Herring Prospectus as an approval and verification of all the contents as mentioned in the Red Herring Prospectus.

RESOLVED FURTHER THAT Saurabh Garg, Chairman & Managing Director and/ or Amita Garg, Non-Executive Director of the Company be and are hereby authorized to deliver the copy of the approved Red Herring Prospectus, duly signed by all the Directors in their respective capacities along with the Chief Financial Officer and Company Secretary & Compliance officer of the Company, to the Book Running Lead Managers of the Issue i.e. Hem Securities Limited and Share India Capital Services Private Limited, for deposition of the same with NSE Emerge.

RESOLVED FURTHER THAT any of the Directors and/ or Key Managerial Personnel of the Company be and are hereby severally authorized to do all such acts, deeds, matters and things as it may in its absolute discretion consider necessary, desirable or expedient and to sign, execute and submit all the requisite documents, in connection with the said filing of the Red Herring Prospectus with NSE Emerge.

Q-LINE BIOTECH LIMITED

(Formerly known as “Q-Line Biotech Private Limited”)

RESOLVED FURTHER THAT a certified true copy of the resolution be furnished under the signature of any one Director and/or Key Managerial Personnel of the Company to the respective authorities”.

// Certified True Copy //

**For Q-Line Biotech Limited
Formerly Known As Q-Line Biotech Private Limited**

Q-LINE BIOTECH LIMITED



Managing Director & Chairman

Saurabh Garg
Chairman & Managing Director
DIN: 02891621
Address: 280/9KHA, Durga Puri, Near Post Office,
Blunt Square, Mawaiya, Rajendranagar,
Lucknow, Uttar Pradesh, 226004

Date: May 16, 2026

Q-LINE BIOTECH LIMITED

(Formerly known as “Q-Line Biotech Private Limited”)

Regd. Office: 298-281, Transport Nagar, Kanpur Road, Adjacent. Transport Nagar Metro Station, Lucknow-226012 (U.P.), INDIA. Tel.: 0522-2433023
Delhi. Office: C-108, Naraina Industrial Area Phase -1, New Delhi, Delhi, 110028. Tel.: 011-45577407
E-mail: compliance@qlinebiotech.com | Website: www.qlinebiotech.com | CIN No.: U74120UP2010PLC042528